856 results on '"Boumpas, Dimitrios T."'
Search Results
2. Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study
3. Transcriptomic and proteomic profiling reveals distinct pathogenic features of peripheral non-classical monocytes in systemic lupus erythematosus
4. Enhanced and stabilized mesenchymal stem cell growth inside plasma pre-treated and collagen-coated PDMS-based microfluidic chambers
5. IL‐1β/DNA complex elevation distinguishes autoinflammatory disorders from autoimmune and infectious diseases
6. Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations
7. Can we predict kidney involvement in patients with systemic lupus erythematosus? A retrospective cohort study with independent validation
8. Single-cell transcriptomic analysis of hematopoietic progenitor cells from patients with systemic lupus erythematosus reveals interferon-inducible reprogramming in early progenitors
9. Converging evidence of impaired brain function in systemic lupus erythematosus: changes in perfusion dynamics and intrinsic functional connectivity
10. Targeted genotyping of COVID-19 patients reveals a signature of complement C3 and factor B coding SNPs associated with severe infection
11. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus
12. Early prediction of COVID-19 outcome using artificial intelligence techniques and only five laboratory indices
13. Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN-signature and distinct molecular profiles in venous versus arterial events
14. Regional european genetic ancestry predicts type I interferon level and risk of severe viral infection
15. Enhanced medullary and extramedullary granulopoiesis sustain the inflammatory response in lupus nephritis
16. O13 Innate immunity transcriptional profiles as potential predictive biomarkers for treatment response in systemic lupus erythematosus: Insights from a longitudinal study
17. P88 Baseline factors associated with subsequent development of incident nephritis in patients with systemic lupus erythematosus: a retrospective cohort study
18. P92 Quantifying the unmet need in lupus nephritis: EULAR/ERA- EDTA treatment targets, flares, and treatment modifications in the first year in a multicenter observational study
19. P97 LNMap: a curated computational resource of molecular pathways in lupus nephritis
20. Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus
21. First Diagnosis of Systemic Lupus Erythematosus in Hospitalized Patients: Clinical Phenotypes and Pitfalls for the Non-Specialist
22. Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression
23. Impaired serotonin synthesis in hippocampus of murine lupus represents an early neuropsychiatric event
24. Fludarabine in Nonmalignant Disorders
25. Fabrication of a 3D microfluidic cell culture device for bone marrow-on-a-chip
26. Mitochondrial Oxidative Damage Underlies Regulatory T Cell Defects in Autoimmunity
27. Impaired serotonin synthesis in hippocampus of murine lupus represents an early neuropsychiatric event.
28. Health-related quality of life in patients with ANCA vasculitides compared to rheumatoid arthritis: a cross-sectional comparative study.
29. Serious infections in ANCA-associated vasculitides in the biologic era: real-life data from a multicenter cohort of 162 patients
30. Patrolling human SLE haematopoietic progenitors demonstrate enhanced extramedullary colonisation; implications for peripheral tissue injury
31. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
32. Clinical and Biomarker Responses to BI 655064, an Antagonistic Anti‐CD40 Antibody, in Patients With Active Lupus Nephritis: A Randomized, Double‐Blind, Placebo‐Controlled, Phase II Trial
33. Contributors
34. Cytotoxic drug treatment
35. A network-based approach reveals long non-coding RNAs associated with disease activity in lupus nephritis: key pathways for flare and potential biomarkers to be used as liquid biopsies
36. Altered hippocampal connectivity dynamics predicts memory performance in neuropsychiatric lupus: a resting-state fMRI study using cross-recurrence quantification analysis
37. Investigating the role of “Immature Myeloid Cells” as Drivers of Inflammation and Disease Persistence in Psoriatic Arthritis
38. NF-kappa-B essential modulator (NEMO) gene polymorphism in an adult woman with systemic lupus erythematosus and recurrent non-tuberculous mycobacterial disseminated infections
39. Health-related quality of life in patients with ANCA vasculitides compared to rheumatoid arthritis: a cross-sectional comparative study
40. Extensive fragmentation and re-organization of transcription in Systemic Lupus Erythematosus
41. Real-world effectiveness of golimumab in the treatment of patients with active rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who failed initial TNF-α inhibitor therapy: a pooled analysis of European prospective observational studie
42. Annals of the Rheumatic Diseases collection on lupus nephritis (2019–2022): novel insights and advances in therapy
43. Down‐regulation of human long non‐coding RNA LINC01187 is associated with nephropathies
44. Data from Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors
45. Figure S1, Figure S2, Table S1 from Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors
46. The genomic landscape of ANCA-associated vasculitis: Distinct transcriptional signatures, molecular endotypes and comparison with systemic lupus erythematosus
47. Microglia activation in the presence of intact blood–brain barrier and disruption of hippocampal neurogenesis via IL-6 and IL-18 mediate early diffuse neuropsychiatric lupus
48. 2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice
49. Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider
50. Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.